Catalog No.
DHA04501
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG4-lambda
Clonality
Monoclonal
Target
Mannan-binding lectin serine protease 2, Mannose-binding protein-associated serine protease 2, MASP-2, MBL-associated serine protease 2, MASP2
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
O00187
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
OMS721, CAS: 2108782-45-0
Clone ID
Narsoplimab
Endothelial injury and thrombotic microangiopathy in COVID-19: Treatment with the lectin-pathway inhibitor narsoplimab, PMID: 32943233
Safety, Tolerability and Efficacy of Narsoplimab, a Novel MASP-2 Inhibitor for the Treatment of IgA Nephropathy, PMID: 33163724
Antibodies to watch in 2020, PMID: 31847708
MASP2 levels are elevated in thrombotic microangiopathies: association with microvascular endothelial cell injury and suppression by anti-MASP2 antibody narsoplimab, PMID: 32681658
Inhibition of the Lectin Pathway of the Complement System as a Novel Approach in the Management of IgA Vasculitis-Associated Nephritis, PMID: 32721954
Lectin Pathway Mediates Complement Activation by SARS-CoV-2 Proteins, PMID: 34290717
Transplant-associated thrombotic microangiopathy: theoretical considerations and a practical approach to an unrefined diagnosis, PMID: 33875812
Translating biomarker insights into practice: a path forward in TA-TMA management., PMID:40406401
Narsoplimab for refractory transplantation-associated thrombotic microangiopathy (TA-TMA) in adult patients receiving allogeneic hematopoietic stem cell transplantation (AHSCT)., PMID:40263635
Therapy of IgA nephropathy: time for a paradigm change., PMID:39211339
Safety and efficacy of narsoplimab in pediatric and adult patients with transplant-associated thrombotic microangiopathy: a real-world experience., PMID:38773280
Successful use of narsoplimab to treat allogeneic transplant-associated thrombotic microangiopathy while maintaining sirolimus., PMID:38467748
Advances in the treatment of IgA nephropathy with biological agents., PMID:38450299
Compassionate Use Narsoplimab for Severe Refractory Transplantation-Associated Thrombotic Microangiopathy in Children., PMID:38145741
Development and characterization of narsoplimab, a selective MASP-2 inhibitor, for the treatment of lectin-pathway-mediated disorders., PMID:38022610
A narrative review of potential drug treatments for nephritis in children with IgA vasculitis (HSP)., PMID:37755547
Complement inhibitors in pediatric kidney diseases: new therapeutic opportunities., PMID:37733095
MASP2 inhibition by narsoplimab suppresses endotheliopathies characteristic of transplant-associated thrombotic microangiopathy: in vitro and ex vivo evidence., PMID:37191586
Emerging role of monoclonal antibodies in the treatment of IgA nephropathy., PMID:37183663
Narsoplimab for severe transplant-associated thrombotic microangiopathy., PMID:36915123
Transplant-Associated Thrombotic Microangiopathy in the Context of Allogenic Hematopoietic Stem Cell Transplantation: Where We Stand., PMID:36674666
Complement System as a New Target for Hematopoietic Stem Cell Transplantation-Related Thrombotic Microangiopathy., PMID:35890144
Narsoplimab, a Mannan-Binding Lectin-Associated Serine Protease-2 Inhibitor, for the Treatment of Adult Hematopoietic Stem-Cell Transplantation-Associated Thrombotic Microangiopathy., PMID:35439028
Advancing therapeutic complement inhibition in hematologic diseases: PNH and beyond., PMID:34482398
Lectin Pathway Mediates Complement Activation by SARS-CoV-2 Proteins., PMID:34290717
Transplant-associated thrombotic microangiopathy: theoretical considerations and a practical approach to an unrefined diagnosis., PMID:33875812
Safety, Tolerability and Efficacy of Narsoplimab, a Novel MASP-2 Inhibitor for the Treatment of IgA Nephropathy., PMID:33163724
Endothelial injury and thrombotic microangiopathy in COVID-19: Treatment with the lectin-pathway inhibitor narsoplimab., PMID:32943233
Inhibition of the Lectin Pathway of the Complement System as a Novel Approach in the Management of IgA Vasculitis-Associated Nephritis., PMID:32721954
MASP2 levels are elevated in thrombotic microangiopathies: association with microvascular endothelial cell injury and suppression by anti-MASP2 antibody narsoplimab., PMID:32681658
Antibodies to watch in 2020., PMID:31847708
For research use only. Not for human or drug use.
